U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H19NO2.H2O4S
Molecular Weight 307.363
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAMETHAN MONOSULFATE

SMILES

OS(O)(=O)=O.CCCCNCC(O)C1=CC=C(O)C=C1

InChI

InChIKey=LHQHLXHNHWARAM-UHFFFAOYSA-N
InChI=1S/C12H19NO2.H2O4S/c1-2-3-8-13-9-12(15)10-4-6-11(14)7-5-10;1-5(2,3)4/h4-7,12-15H,2-3,8-9H2,1H3;(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula C12H19NO2
Molecular Weight 209.2848
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bamethan (butyl-sympatol or vasculat) is an adrenaline derivative developed by C. H. Boehringer Sohn. Bamethan shows a depressor action on peripheral blood vessels as a result of the peripheral vasodilating action caused by stimulation of adrenergic beta-receptor. Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VASCULAT

Approved Use

Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.
PubMed

PubMed

TitleDatePubMed
The effect of bamethan on cardiovascular response.
1966 Jan-Feb
Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum.
2002 Jun 20
Tandem mass spectrometry with online high-flow reversed-phase extraction and normal-phase chromatography on silica columns with aqueous-organic mobile phase for quantitation of polar compounds in biological fluids.
2005

Sample Use Guides

75-100 mg
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:43:28 GMT 2023
Edited
by admin
on Sat Dec 16 09:43:28 GMT 2023
Record UNII
4PG1X4EJ8G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAMETHAN MONOSULFATE
Common Name English
BENZENEMETHANOL, .ALPHA.-((BUTYLAMINO)METHYL)-4-HYDROXY-, SULFATE (1:1)
Systematic Name English
2-N-BUTYLAMINO-1-(P-HYDROXYPHENYL)ETHANOL SULFATE
Systematic Name English
1-(4-HYDROXYPHENYL)-2-BUTYLAMINOETHANOL-SULFATE
Systematic Name English
VASCUL SULFATE
Brand Name English
Code System Code Type Description
CAS
5011-27-8
Created by admin on Sat Dec 16 09:43:28 GMT 2023 , Edited by admin on Sat Dec 16 09:43:28 GMT 2023
PRIMARY
FDA UNII
4PG1X4EJ8G
Created by admin on Sat Dec 16 09:43:28 GMT 2023 , Edited by admin on Sat Dec 16 09:43:28 GMT 2023
PRIMARY
PUBCHEM
12883785
Created by admin on Sat Dec 16 09:43:28 GMT 2023 , Edited by admin on Sat Dec 16 09:43:28 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY